Form 4: United Therapeutics Director Rothblatt Executes Stock Option Exercise and Sale Under 10b5-1 Plan
SEC Form 4
Director Martine Rothblatt exercised stock options and sold shares of United Therapeutics Corp (UTHR) on May 22, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- On May 22, 2024, Martine Rothblatt, a director at United Therapeutics Corp (UTHR), executed stock options and sold shares of common stock.
- These transactions were conducted under a pre-arranged 10b5-1 trading plan established on August 4, 2023.
- Rothblatt exercised 3,600 stock options at a price of $129.49 per share.
- The sales of common stock occurred in multiple trades at varying prices, with weighted average prices reported for each transaction.
- The sales prices ranged from $275.2273 to $277.8534 per share.
- Following these transactions, Rothblatt directly owns 130 shares of common stock and indirectly owns a significant number of shares through various family trusts.
- The 10b5-1 trading plan is set to continue until the earlier of the exhaustion of 723,869 stock options expiring on December 31, 2024, or August 31, 2024.
Sentiment
Score: 6
Explanation: The sentiment is neutral as the transactions are part of a pre-arranged trading plan and do not necessarily indicate a change in the director's confidence in the company.
Positives
- The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating that the sales were planned well in advance and not based on any recent insider information.
Future Outlook
The 10b5-1 trading plan will continue until the earlier of August 31, 2024, or the exhaustion of 723,869 stock options expiring on December 31, 2024.
Industry Context
Directors and officers often use 10b5-1 trading plans to sell company stock over a period of time to avoid accusations of insider trading. This filing indicates routine transactions under such a plan.
Comparison to Industry Standards
- The use of 10b5-1 trading plans is a common practice among corporate executives to manage their stock holdings while complying with insider trading regulations.
- Companies like Pfizer, Apple, and Microsoft have executives who utilize similar plans to execute stock transactions periodically.
- The size and frequency of these transactions are typical for directors managing their personal finances and stock option grants.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the small volume of shares sold compared to the total outstanding shares.
- The impact on employees, customers, suppliers, and creditors is expected to be negligible.
Key Dates
| Date | Description |
|---|---|
| 2014-12-31 | Original expiration date of the stock options exercised. |
| 2023-08-04 | Date the 10b5-1 trading plan was entered into by the reporting person. |
| 2024-05-22 | Date of the stock option exercise and sale of shares. |
| 2024-08-31 | Potential end date of the 10b5-1 trading plan. |
| 2024-12-31 | Expiration date of the tranche of 723,869 stock options under the 10b5-1 trading plan. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.